NCT03320642 2025-10-21GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host DiseaseIncyte CorporationPhase 1 Terminated84 enrolled
NCT01663766 2021-08-19Phase I Study of Milatuzumab for Graft Versus Host DiseaseGilead SciencesPhase 1 Terminated12 enrolled
NCT00967343 2021-06-14Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical DonorKiadis PharmaPhase 2/3 Terminated40 enrolled 10 charts
NCT00003056 2021-05-06Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell TransplantationTakedaPhase 3 Terminated105 enrolled
NCT00781781 2015-02-04Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity ConditioningCABYCPhase 2 Terminated34 enrolled
NCT00756912 2014-07-11A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related DonorsEisai Inc.Phase 1 Terminated30 enrolled